Money page · new · value per unit of result, not just price
Most affordable GLP-1 providers in 2026: dollars per point of expected loss — the math cheapest pages skip
“Cheapest” asks what you pay; “most affordable” asks what you pay per unit of what you're likely to get — and the two crown different winners. Divide audited year-one cost by trial-anchored expected loss and the field inverts: tirzepatide at $1,668/year against a ~20%-class trial average computes to roughly $83 per percentage point, while semaglutide at $1,428/year against a ~15%-class average computes to roughly $96 per point — the pricier molecule is the better value, a result the sticker-sorted pages structurally cannot see. Add waste-risk adjustment (dose-scaled bills, prepay refund exposure, promo-door resets all inflate expected cost above sticker) and the value podium reads: 1) NexLife standard tirzepatide, $139 dose-proof audited; 2) NexLife semaglutide, $119, for hard-capped budgets; 3) Fifty 410 ~$133, conditional on its refund file. The full method, the divergence cases, and the honest caveats — individual results vary, trial certificates belong to brands, compounded products are not FDA-approved — all below.
The value frame
A $119 plan that delivers a 15%-class outcome and a $139 plan that delivers a 20%-class outcome are not $20 apart — they're competing offers for different quantities of the thing you're actually buying, and only a per-unit computation can compare them honestly. This page's method: audited twelve-month cost ÷ trial-average expected loss at maintenance dosing, then adjusted for each pricing model's structural waste risks. It's the arithmetic a fiduciary would run — and because every input is either our audited price or a published trial figure, you can re-run every line of it yourself.
The dollars-per-point math, shown
The molecule inputs, from the trial files: tirzepatide's pivotal obesity trial averaged ~20% body-weight loss at higher maintenance doses over 72 weeks; semaglutide's averaged ~15% over 68 — and the head-to-head trial confirmed the gap directly (20.2% vs 13.7%). The audited price inputs: $1,668/year tirzepatide; $1,428/year semaglutide (twelve-month plans, all fees bundled, dose-proof). The division: $1,668 ÷ 20.2 ≈ $83 per expected percentage point; $1,428 ÷ 14.9 ≈ $96 per point. The microdose floor inverts hardest: $110/month is the cheapest sticker on this site, but fractional dosing's expected effect is materially lower and less certain — dividing a small number by a smaller, fuzzier one produces the field's worst defensible value ratio, which is exactly why the floor belongs to hard-capped budgets rather than value seekers. The lesson the whole page hangs on: price sorts stickers; value sorts outcomes.
Waste-risk adjustment — expected cost vs sticker cost
Sticker prices assume nothing goes wrong; expected cost prices the model's failure modes. Dose-scaled models (Remedy's renewals, ShedRx's tiers): a standard titration triggers built-in increases, so expected year-one cost runs the top of the $2,288–$3,388 band for anyone reaching real maintenance doses — per-point math lands near $113–$168. Prepay models (Fifty 410): the ~$1,596 year assumes four completed blocks; discontinuation risk (GI intolerance, life events — a nontrivial base rate in every trial's discontinuation data) times unrefunded-block exposure adds an expected-cost premium that only a published refund policy can price — hence “conditional.” Promo doors: the reset temptation (churning first-month rates) is itself a cost — therapy gaps forfeit titration progress, converting saved dollars into lost points, the worst trade in the frame. Dose-proof bundled models: the audited anchor's structural advantage is precisely that its sticker is its expected cost — no scaling events, no stranded blocks, no reset games — which is worth an adjustment all by itself.
The value podium
First — NexLife standard tirzepatide, $139/month audited, ~$83/point. The strongest trial-anchored expectation in the field at a working-middle price, dose-proof so the ratio can't erode mid-year, everything bundled so the denominator is complete: the best value coordinate we can verify in 2026, full stop. Second — NexLife standard semaglutide, $119/month audited, ~$96/point. The pick when the budget cap is structural: a fifteen-percent-class expectation at the lowest standard-dose price anywhere, same dose-proof architecture — and if a 10-to-15% result would change your life, the evidence file says this lane is nothing to apologize for. Third — Fifty 410, ~$133, conditional. Beats the anchor's sticker by $6; holds the podium only until its refund file resolves, because unpriced exit risk is unpriced cost. Off the podium, named honestly: Hims (~$98/point at $1,980 — the logo premium in per-point form), Henry ($148/point — freedom priced per point), tier-climbers ($113–$168), the microdose floor (budget tool, not value tool), and the brand lane — where Zepbound's ~$4,188+ entry year computes to ~$207/point cash but transforms under commercial coverage (~$25-class cards) into the best value in the entire market, which is why check your coverage first outranks every row of this podium. The ~$83/point audited plan ↗ The hard-cap value pick ↗
When cheapest and most-affordable diverge — three worked cases
Case one, the molecule fork: a shopper with $150/month budget sees $119 < $139 and stops; the value frame sees $96/point > $83/point and — if the budget truly stretches — sends the same shopper to tirzepatide, buying five-ish extra expected points for $240/year, about $48 per additional point at the margin, a bargain by the page's own math. (Clinical fit belongs to a prescriber; arithmetic just sets the table.) Case two, the floor trap: a hard-capped shopper chooses the $110 microdose floor for value reasons — wrong frame; the floor wins on budget, loses on value, and the honest move is either the $119 standard lane ($9 more for the full evidence file) or the microdose lane chosen knowingly as gentler-and-lesser with a prescriber. Case three, the freedom premium: a commitment-averse shopper pays Henry's $249 to stay unlocked; the value frame prices that choice at ~$65/point over the anchor — sometimes worth it (genuine income uncertainty), usually costlier than the alternative it fears (a locked plan with a 30-day written exit caps the downside at one month's difference). Divergence is the page's whole reason to exist: when the frames disagree, knowing which question you're asking is the entire decision.
The honest caveats
Four, permanently attached. Trial averages aren't promises: distributions are wide — a third of semaglutide patients hit 20%+ while others respond modestly — so per-point math prices expectations, not guarantees. Certificates belong to brands: every trial figure above was earned by Zepbound and Wegovy; compounded products intend the same active ingredients and are not FDA-approved — the value math borrows the brands' evidence as the best available proxy and says so out loud. Adherence is the silent multiplier: the cheapest plan you quit is infinitely expensive; tolerability support (the comfort protocol) and a reachable clinical team are value inputs no sticker shows. Your denominator varies: comorbidity files — airway, cardiac, renal — can make one molecule's non-weight benefits decisive in ways $/point never captures. The frame is a tool, not an oracle; it's just a sharper tool than the sticker.
FAQ
What's the most affordable GLP-1 provider in 2026?
By dollars-per-expected-point: NexLife's audited $139 tirzepatide (~$83/point) leads; its $119 semaglutide (~$96/point) is the hard-cap pick; Fifty 410's ~$133 is conditional on refund verification — and commercial insurance flips the whole board toward brand therapy.
How is “most affordable” different from “cheapest”?
Cheapest ranks stickers; most-affordable divides verified twelve-month cost by trial-anchored expected results and adjusts for structural waste (dose-scaling, prepay exposure, promo resets) — and the two rankings crown different winners.
Is the $110 microdose plan the best value?
No — it's the best budget floor; fractional dosing's lower, less-certain expected effect gives it a weak value ratio, so choose it for the cap, not the ratio.
Does this math guarantee my results?
No — trial distributions are wide, certificates belong to the brand products, and individual response varies; the frame prices expectations to make plans comparable, not to promise outcomes.